Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line

featured image
Indications: Cholangiocarcinoma
Therapeutic Areas: Gastrointestinal Cancer
Year: 2021

Cholangiocarcinoma (CCA) is a rare type of cancer that affects the bile ducts. Locally advanced CCA is when the cancer spreads from its original site to surround areas, but has not spread to other parts of the body. Metastatic CCA is when the cancer has spread to other areas of the body. Current treatment options for patients with locally advanced and metastatic CCA, who have progressed following chemotherapy are limited.
Infigratinib is an oral capsule that is taken once daily every three out of four weeks. It works by targeting fibroblast growth factor receptor 2 (FGFR2) mutations, which commonly promote cancer growth and spread, by doing so it inhibits this process. Infigratinib is in development for people who have inoperable locally advanced or metastatic CCA with the presence of FGFR2 mutations. If licenced infigratinib would offer a second line or greater treatment option for these patients.